Collegium Pharmaceutical, Inc. (COLL)

Nasdaq Health Care Pharmaceuticals S&P SmallCap 600

$24.21

-0.95 (-3.78%)

Close of Nov 06, 2026 · end-of-day data

Source: Collegium Pharmaceutical, Inc.'s 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 06, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.71M	$28.48M	$280.41M	$296.70M	$310.02M	$276.87M	$463.93M	$566.77M	$631.45M	$780.57M
Cost of revenue	$213.00K	$2.60M	$165.68M	$193.66M	$130.18M	$126.25M	$254.44M	$240.60M	$254.10M	$317.31M
Gross profit	$1.50M	$25.88M	$114.74M	$103.04M	$179.84M	$150.62M	$209.49M	$326.17M	$377.34M	$463.26M
Research & development	$14.95M	$8.57M	$8.66M	$10.34M	$9.77M	$9.45M	$3.98M	$0	$0	—
Selling, general & admin	$80.63M	$92.76M	$126.76M	$116.45M	$113.83M	$118.96M	$172.19M	$159.21M	$210.36M	$284.80M
Operating income	-$94.08M	-$75.45M	-$20.68M	-$23.75M	$56.23M	$17.63M	$33.32M	$166.96M	$169.90M	$179.64M
Interest expense	$94.00K	—	$20.13M	$909.00K	$28.88M	$21.01M	$63.21M	$83.34M	$73.97M	$82.31M
Pre-tax income	—	—	-$39.13M	-$22.72M	$27.58M	-$3.37M	-$28.85M	$75.73M	$98.57M	$92.62M
Income tax	—	—	—	$0	$830.00K	-$74.89M	-$3.85M	$27.58M	$29.38M	$29.75M
Net income	-$94.18M	-$74.86M	-$39.13M	-$22.72M	$26.75M	$71.52M	-$25.00M	$48.16M	$69.19M	$62.87M
EBITDA	-$93.43M	-$74.85M	-$19.61M	-$23.02M	$57.10M	$19.36M	$36.00M	$170.46M	$173.75M	$183.82M
EPS (basic)	$-3.88	$-2.47	$-1.19	$-0.68	$0.78	$2.05	$-0.74	$1.43	$2.14	$1.98
EPS (diluted)	$-3.88	$-2.47	$-1.19	$-0.68	$0.76	$1.86	$-0.74	$1.29	$1.86	$1.73
Diluted shares	24.26M	30.27M	32.95M	33.45M	35.15M	41.05M	33.83M	41.79M	40.42M	39.70M
Gross margin	87.6%	90.9%	40.9%	34.7%	58.0%	54.4%	45.2%	57.5%	59.8%	59.3%
Operating margin	-5498.7%	-264.9%	-7.4%	-8.0%	18.1%	6.4%	7.2%	29.5%	26.9%	23.0%
Net margin	-5504.1%	-262.9%	-14.0%	-7.7%	8.6%	25.8%	-5.4%	8.5%	11.0%	8.1%

Balance sheet

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$153.22M	$118.70M	$146.63M	$170.02M	$174.12M	$186.43M	$173.69M	$238.95M	$70.56M	$231.25M
Short-term investments	—	—	—	—	—	—	$0	$71.60M	$92.20M	$155.43M
Receivables	$2.13M	$9.97M	$77.95M	$72.95M	$83.32M	$105.84M	$183.12M	$179.53M	$228.54M	$211.33M
Inventory	$1.32M	$1.81M	$7.82M	$9.64M	$15.61M	$17.39M	$46.50M	$32.33M	$35.56M	$40.91M
Total current assets	$158.57M	$133.48M	$237.51M	$255.72M	$277.89M	$315.54M	$419.99M	$537.60M	$482.26M	$691.41M
Goodwill	—	—	—	—	—	—	$133.69M	$133.86M	$162.33M	$145.93M
Total assets	$162.02M	$135.57M	$291.25M	$306.30M	$643.84M	$692.08M	$1.17B	$1.14B	$1.66B	$1.66B
Total current liabilities	$25.60M	$31.49M	$189.13M	$201.76M	$239.45M	$279.57M	$433.73M	$457.92M	$509.51M	$440.03M
Long-term debt	$4.15M	—	$11.50M	$11.50M	—	—	—	—	—	—
Total debt	$4.15M	—	$11.50M	$11.50M	—	—	—	—	—	—
Total liabilities	$27.11M	$31.49M	$199.66M	$218.87M	$457.81M	$489.15M	$979.29M	$947.88M	$1.43B	$1.36B
Shareholders' equity	$134.91M	$104.08M	$91.58M	$87.43M	$186.03M	$202.93M	$194.84M	$195.43M	$228.84M	$301.68M

Cash flow

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	-$75.05M	-$67.02M	$169.39M	$27.78M	$93.94M	$103.56M	$124.23M	$274.75M	$204.98M	$329.32M
Capital expenditures	$477.00K	$990.00K	$5.48M	$6.44M	$5.55M	$1.94M	$1.62M	$461.00K	$1.65M	$1.74M
Free cash flow	-$75.53M	-$68.01M	$163.91M	$21.34M	$88.40M	$101.61M	$122.61M	$274.29M	$203.33M	$327.58M
Investing cash flow	-$2.98M	-$990.00K	-$24.35M	-$6.44M	-$373.77M	-$1.94M	-$573.69M	-$70.81M	-$287.76M	-$63.53M
Financing cash flow	$135.56M	$33.48M	-$117.20M	$2.04M	$286.47M	-$89.30M	$436.72M	-$140.18M	-$60.60M	-$110.25M
Share buybacks	—	—	—	—	—	$47.86M	$14.06M	$75.00M	$60.02M	$25.10M
Stock-based compensation	$5.79M	$7.95M	$13.78M	$16.53M	$21.91M	$24.25M	$22.87M	$27.14M	$32.40M	$41.91M
Depreciation & amortization	$655.00K	$594.00K	$1.07M	$731.00K	$870.00K	$1.74M	$2.68M	$3.50M	$3.86M	$4.18M

Income statement

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	$149.75M	$144.92M	$145.28M	$159.30M	$181.95M	$177.76M	$188.00M	$209.36M	$205.45M	$193.52M	$199.88M	$216.34M
Cost of revenue	$55.12M	$53.47M	$54.47M	$62.51M	$83.66M	$80.43M	$79.62M	$80.19M	$77.07M	$76.27M	$89.59M	$90.92M
Gross profit	$94.63M	$91.46M	$90.81M	$96.79M	$98.29M	$97.32M	$108.38M	$129.17M	$128.38M	$117.25M	$110.29M	$125.42M
Selling, general & admin	$32.94M	$41.98M	$43.34M	$61.95M	$63.09M	$76.42M	$73.64M	$67.10M	$67.64M	$86.35M	$106.59M	$99.59M
Operating income	$61.69M	$49.47M	$47.47M	$34.84M	$38.11M	$21.69M	$35.10M	$62.09M	$60.76M	$30.90M	$3.70M	$28.72M
Interest expense	$19.28M	$17.34M	$15.59M	$18.39M	$22.65M	$20.79M	$20.46M	$21.77M	$19.29M	$15.86M	$19.52M	$21.94M
Pre-tax income	$46.71M	$36.62M	$29.10M	$15.58M	$17.27M	$3.12M	$17.02M	$43.44M	$29.04M	$18.74M	-$13.53M	$7.91M
Income tax	$14.77M	$8.91M	$9.49M	$6.25M	$4.73M	$705.00K	$5.04M	$11.93M	$12.07M	$4.24M	$1.52M	-$13.85M
Net income	$31.94M	$27.71M	$19.61M	$9.34M	$12.54M	$2.42M	$11.98M	$31.51M	$16.96M	$14.50M	-$15.05M	$21.76M
EBITDA	$62.64M	$50.39M	$48.42M	$35.78M	$39.15M	$22.78M	$36.24M	$63.12M	$61.68M	$31.36M	$5.51M	$29.21M
EPS (basic)	$0.99	$0.86	$0.60	$0.29	$0.39	$0.08	$0.38	$1.00	$0.54	$0.45	$-0.46	$0.69
EPS (diluted)	$0.82	$0.71	$0.52	$0.27	$0.36	$0.07	$0.34	$0.84	$0.46	$0.40	$-0.46	$0.60
Diluted shares	41.28M	41.44M	40.38M	40.16M	40.11M	32.84M	39.08M	39.44M	40.08M	40.07M	32.46M	39.11M
Gross margin	63.2%	63.1%	62.5%	60.8%	54.0%	54.8%	57.7%	61.7%	62.5%	60.6%	55.2%	58.0%
Operating margin	41.2%	34.1%	32.7%	21.9%	20.9%	12.2%	18.7%	29.7%	29.6%	16.0%	1.9%	13.3%
Net margin	21.3%	19.1%	13.5%	5.9%	6.9%	1.4%	6.4%	15.0%	8.3%	7.5%	-7.5%	10.1%

Balance sheet

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Cash & equivalents	$238.95M	$228.61M	$172.89M	$38.96M	$70.56M	$96.19M	$117.35M	$150.10M	$231.25M	$268.65M	$129.47M	$144.80M
Short-term investments	$71.60M	$89.44M	$98.74M	$81.00M	$92.20M	$101.58M	$104.81M	$135.77M	$155.43M	$153.10M	$0	$0
Receivables	$179.53M	$174.69M	$183.85M	$228.46M	$228.54M	$228.71M	$213.02M	$233.95M	$211.33M	$228.76M	$285.10M	$310.79M
Inventory	$32.33M	$31.28M	$27.86M	$38.03M	$35.56M	$37.22M	$38.15M	$38.05M	$40.91M	$42.74M	$113.27M	$88.20M
Total current assets	$537.60M	$539.26M	$510.20M	$443.81M	$482.26M	$527.55M	$549.21M	$613.87M	$691.41M	$745.67M	$608.01M	$611.75M
Goodwill	$133.86M	$133.86M	$133.86M	$145.96M	$162.33M	$150.76M	$147.94M	$145.93M	$145.93M	$145.93M	$190.18M	$193.88M
Total assets	$1.14B	$1.11B	$1.05B	$1.64B	$1.66B	$1.63B	$1.59B	$1.61B	$1.66B	$1.65B	$2.14B	$2.10B
Total current liabilities	$457.92M	$446.44M	$461.72M	$459.43M	$509.51M	$486.71M	$464.61M	$452.93M	$440.03M	$434.97M	$589.86M	$603.09M
Total liabilities	$947.88M	$892.08M	$836.80M	$1.40B	$1.43B	$1.40B	$1.36B	$1.33B	$1.36B	$1.34B	$1.82B	$1.80B
Shareholders' equity	$195.43M	$222.17M	$216.58M	$234.28M	$228.84M	$234.43M	$232.21M	$274.81M	$301.68M	$312.42M	$311.91M	$296.44M

Cash flow

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Operating cash flow	$73.34M	$61.94M	$67.40M	-$9.00M	$84.64M	$55.40M	$72.44M	$78.44M	$123.05M	$57.11M	$71.32M	$86.54M
Capital expenditures	$164.00K	$568.00K	$270.00K	$244.00K	$570.00K	$798.00K	$65.00K	$188.00K	$689.00K	$270.00K	$496.00K	$277.00K
Free cash flow	$73.17M	$61.37M	$67.13M	-$9.24M	$84.07M	$54.60M	$72.37M	$78.25M	$122.36M	$56.84M	$70.83M	$86.26M
Investing cash flow	-$25.10M	-$18.13M	-$8.91M	-$248.96M	-$11.76M	-$9.68M	-$2.92M	-$30.87M	-$20.07M	$1.63M	-$502.59M	-$277.00K
Financing cash flow	-$67.83M	-$54.15M	-$114.21M	$149.03M	-$41.28M	-$25.24M	-$48.37M	-$14.82M	-$21.82M	-$21.34M	$292.09M	-$70.93M
Share buybacks	$25.00M	—	—	$0	$25.02M	—	$25.10M	$0	$0	—	$0	—
Stock-based compensation	$7.00M	$7.47M	$10.01M	$7.32M	$7.60M	$11.52M	$10.82M	$9.81M	$9.75M	$10.88M	$14.48M	$12.45M
Depreciation & amortization	$949.00K	$917.00K	$952.00K	$946.00K	$1.04M	$1.09M	$1.14M	$1.03M	$923.00K	$463.00K	$1.81M	$491.00K

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.